Publications
-
01.04.2024Fed. Circ. Patent Decisions In 2023: An Empirical ReviewArticlesThis annual article provides an empirical review of the U.S. Court of Appeals for the Federal Circuit's decisions in patent cases during calendar year 2023.
-
01.09.2023Fed. Circ. Patent Decisions in 2022: An Empirical ReviewArticlesThis article provides an empirical review of the U.S. Court of Appeals for the Federal Circuit's decisions in patent cases during calendar year 2022.
-
01.06.2022Fed. Circ. Patent Decisions In 2021: An Empirical ReviewArticles
Law360
This fifth annual article provides an empirical review of the U.S. Court of Appeals for the Federal Circuit's decisions in patent cases during calendar year 2021. -
01.11.2021Fed. Circ. Patent Decisions In 2020: An Empirical ReviewArticles
Law360
This fourth annual article provides an empirical review of the U.S. Court of Appeals for the Federal Circuit's decisions in patent cases during calendar year 2020.
-
01.09.2020Fed. Circ. Patent Decisions in 2019: An Empirical ReviewArticles
Law360
This article provides an empirical review of the U.S. Court of Appeals for the Federal Circuit’s decisions in patent cases during calendar year 2019.
-
01.18.2018Inequitable Conduct Renders U.S. Patent UnenforceableArticles
IPLead
In an opinion dated July 27, 2017, the CAFC held in Regeneron Pharmaceuticals v. Merus N.V. (2016-1346) that a patent was unenforceable based on conduct during prosecution of the patent application that resulted in the patent at suit. -
01.05.2018Fed. Circ.'s 2017 Patent Decisions: A Statistical AnalysisArticlesAfter each fiscal year end, the Federal Circuit publishes statistics summarizing where its cases came from, the court’s throughput over the year, and its median times to disposition in cases from different sources.
-
12.15.2017Federal Circuit Rules Out State-Law Remedies for Failure to Participate in the Biosimilars "Patent Dance"UpdatesOn December 14, the Federal Circuit issued a decision that further clarifies the ground rules for disclosures of product information by manufacturers of biosimilar pharmaceutical products. In particular, the Federal Circuit ruled in Amgen Inc. v. Sandoz Inc. that the original sponsors of biologics products cannot invoke state laws to compel applicants that are seeking to market biosimilar products to disclose information about those products under the Biologics Price Competition and Innovation Act (BPCIA).
-
06.13.2017First Impressions: New Strategies in the New Era of Patent Exhaustion After Impression Products v. Lexmark InternationalUpdatesIn Impression Products, Inc. v. Lexmark International, No. 15–1189, 137 S. Ct. ___, 2017 WL 2322830 (May 30, 2017), the U.S. Supreme Court held that a patentee’s sale of a product exhausts all of its U.S. patent rights in that item, regardless of any contractual restrictions the patentee may have imposed on subsequent use or sale of the product and regardless of whether the sale occurs within the U.S. or abroad.
-
12.18.2006Supreme Court Agrees to Revisit Application of Per Se Rule Against Resale Price MaintenanceUpdatesOn December 7, 2006, the U.S. Supreme Court granted certiorari in Leegin Creative Leather Products v. PSKS, Inc., a potential landmark case challenging the long-standing "Dr. Miles" doctrine condemning resale price maintenance and minimum vertical price fixing as per se violations of Section One of the Sherman Act.
Presentations
-
06.16.2020 - 06.19.2020
-
04.03.2018Patent Law Year in ReviewSeminarsPerkins Coie In-house CLE / Palo Alto, CAA review of major patent appellate decisions over the last year by the U.S. Supreme Court and the Federal Circuit.
-
10.26.2017IP Issues Affecting U.S. CorporationsSpeaking EngagementsPerkins Coie / Chicago, ILPatent Litigation practice lunch and learn addressing key patent litigation issues and developments faced by in-house counsel. The program included a sit down with the Honorable Virginia Kendall, who provided a unique view of IP litigation from behind the bench, and panels made up of in-house counsel and our own patent litigation authorities.
-
03.30.2015Perspectives on the Treatment of PTAB Proceedings By Way of AppealSpeaking EngagementsPanelist
Momentum’s 2nd IP Counsel Exchange on Post-Grant Patent Challenges: A Strategic Guide to Effectively Challenging or Defending Patent Validity at the Patent Trial and Appeal Board / San Jose, CA